Wed, 4 Nov
Remus Pharmaceuticals
Remus delivered strong H1 growth led by international operations, though consolidated margins are skewed by a low-margin US distribution transaction.
Summary ready
Earnings calls
Remus Pharmaceuticals concalls
Every Remus Pharmaceuticals earnings call we streamed: the live audio and our summary of what management said.
Calls
Q2 FY27: key takeaways
Call page →Remus delivered strong H1 growth led by international operations, though consolidated margins are skewed by a low-margin US distribution transaction.
Outlook
Targeting 25-30% B2C revenue contribution; H2 expected to outperform H1 based on order book and launches.
Earlier call summaries
All →
15:03 IST
NSE
Earnings Call
Remus Pharmaceuticals Earnings Call: Key Takeaways
Remus Pharmaceuticals delivered 38% YoY consolidated revenue growth for FY26. Management is shifting focus toward higher-margin B2C segments and niche formulations in Latin America and Southeast Asia.
16:11 IST
NSE
Earnings Call
Remus Pharmaceuticals Earnings Call: Key Takeaways
Remus Pharmaceuticals delivered high double-digit revenue growth in H2FY26, driven by aggressive international B2C expansion in Latin America and new specialized therapy launches.
13:05 IST
NSE
Earnings Call
Remus Pharmaceuticals Earnings Call: Key Takeaways
Remus Pharmaceuticals reported FY26 consolidated revenue of ₹8,536 Mn, representing 37.6% growth. The company maintains an asset-light model focusing on complex specialty formulations in semi-regulated markets.
Remus Pharmaceuticals Limited: key numbers
- Share price
- ₹815.00
- Market cap
- ₹960.4 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 26.0×Sector 41.3×
- Promoter holding
- 70.95%
- FII holding
- 5.10%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.